Management

As Chief Executive officer, Dr. Bowlin is responsible for general management, financing and the strategic direction of the company.   Dr. Bowlin has had a distinguished career encompassing over twenty years of anti-infective research, development,  and management experience with pharmaceutical and biotechnology companies.  Dr. Bowlin has extensive experience in drug discovery and development.  Previously, Dr. Bowlin held the positions of Vice President, Research, at BioChem Pharma, and Director of Immunology at Marion Merrell Dow.  Dr. Bowlin's postdoctoral research was done at National Institutes of Health, and predoctoral research at the Cleveland Clinic.  Dr. Bowlin holds a Ph.D. in Cell Biology/Immunology from Cleveland State University.

As Chief Scientific Officer, Dr. Moir provides scientific leadership and direction to Microbiotix and is responsible for overseeing all research, drug development activities and scientific collaborations. Dr. Moir's twenty-five year career has spanned a wide range of molecular biology, encompassing the discovery and validation of antibacterial drug targets, antibacterial drug discovery, bacterial diagnostic marker discovery, human genome physical mapping and cDNA mapping, the discovery of human markers for drug metabolism, and the cloning and expression of heterologous genes in the yeast S. cerevisiae. Previously, Dr. Moir held the positions of Research Director and Scientific Advisor at Genome Therapeutics Corporation. Dr. Moir received a Ph.D. in Biological Chemistry from Harvard University and a B.S. in Chemistry from the University of North Carolina at Chapel Hill. He has authored nearly 50 manuscripts and patent applications.

As Director of Chemistry, Dr. Peet is responsible for direction and management of the Medicinal Chemistry Department at Microbiotix and design of the chemistry for all internal and external research proposals. Dr. Peet is an organic chemist by training and has spent much of his career in big pharma, with the string of companies that led to Aventis (now Sanofi-Aventis). When he left Aventis in 2000 he was Head of Medicinal Chemistry and Distinguished Scientist. He joined the executive team at ArQule as Vice President of Discovery Alliances. At ArQule, he managed alliances with several companies and also built a Drug Discovery Group, which is now still in place as they have evolved into a cancer company (with the acquisition of Cyclis). In 2002, he co-founded and became CEO of Aurigene Discovery Technologies, a drug discovery company, and built laboratories in Boston (Lexington) and Bangalore (India). Dr. Peet has authored 145 journal articles and 65 US patents. He has organized numerous international symposia and serves on several editorial and scientific advisory boards.